New pill targets Hard-to-Treat prostate cancer

NCT ID NCT07172126

Not yet recruiting Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This trial tests an experimental oral drug called TQB3201 in people with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. The drug works by breaking down a key protein that fuels cancer growth, even in cancers with resistance mutations. The study will first check safety and dosing in a small group, then expand to see if it helps control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TQB3201 tablets (an oral targeted protein degrader)
What this could lead to: If successful, this could provide a new treatment option for advanced prostate cancer that has stopped responding to standard hormone therapies.
What could go wrong: This is an early-phase trial (phase I/II) with a small number of participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Cancer Hospital Affiliated to Chongqing University

Chongqing, Chongqing Municipality, 400000, China
Cancer Hospital Affiliated to Fudan University

Shanghai, Shanghai Municipality, 201321, China
The Fifth Affiliated Hospital of Sun Yat-sen University

Zhuhai, Guangdong, 519000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.